Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03389698 · ClinicalTrials.gov registry record
Developing Advanced Blood-Brain Barrier Permeability Imaging for Early AD
A clinical trial of Alzheimer Disease, sponsored by NYU Langone Health.
- Completed
- Registry status
- 27
- Enrollment target
- 1
- Study location
NCT03389698 is a study of Alzheimer Disease that has completed, run by NYU Langone Health. The registered enrollment target is 27 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03389698, a study of Alzheimer Disease, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
Aging is the primary risk factor in aging-related dementia. An important initiating factor for the development and progression of cognitive impairment is disruption of the blood-brain barrier (BBB). BBB plays an important role in maintaining normal brain homeostasis and protecting neural tissues from toxins. It is hypothesized that such changes known to be common in aging and can be an early process that precedes Alzheimer's Disease (AD). The microvascular changes related to subtle BBB disruption can be measured with permeability-surface area (PS) derived from GRASP DCE-MRI acquired less than 10 minutes, and the patterns of increased PS in normal and abnormal aging are different.
Conditions Studied
Interventions
- DEVICE GRASP Dynamic Contrast-Enhanced (DCE) MRI
- DEVICE 3T Brain Scan
- DRUG Gadolinium-based Contrast Agent (GBCA) for MRI
Study Locations (1)
New York
- New York University School of Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2018-12-18 |
| Est. Completion | 2023-07-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03389698
The ClinicalTrials.gov registry entry for NCT03389698 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 3 interventions - of which GRASP Dynamic Contrast-Enhanced (DCE) MRI is the first listed.
NCT03389698 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03389698 about?
NCT03389698 is a clinical study titled "Developing Advanced Blood-Brain Barrier Permeability Imaging for Early AD". Aging is the primary risk factor in aging-related dementia. An important initiating factor for the development and progression of cognitive impairment is disruption of the blood-brain barrier (BBB). BBB plays an important role in maintaining normal brain homeostasis and protecting neural tissues fro...
What is the current status of trial NCT03389698?
This trial is currently completed. The enrollment target is 27 participants. The study started on 2018-12-18. Estimated completion is 2023-07-11.
What conditions does trial NCT03389698 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT03389698?
The interventions under investigation include: GRASP Dynamic Contrast-Enhanced (DCE) MRI (DEVICE), 3T Brain Scan (DEVICE), Gadolinium-based Contrast Agent (GBCA) for MRI (DRUG).
Who is sponsoring clinical trial NCT03389698?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03389698 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.